Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2563393 | 1.00 | CASP3 (0.53) | CASP3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2564007 | 1.00 | CASP3 (0.53) | CASP3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL910267 | 1.00 | CASP3 (0.53) | CASP3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL28682050 | 0.86 | NPC1 (0.50) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL24654500 | 0.86 | KLK7 (0.53) | CASP3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL415617 | 0.86 | CASP3 (0.51) | CASP3ALDH1A1MEN1KMT2AMAPT | |
| Propham SCHEMBL8536412 | 0.85 | SMN1; SMN2 (0.66) | CASP3ALDH1A1MEN1KMT2AMAPT | |
| Propham SCHEMBL67344 | 0.85 | SMN1; SMN2 (0.66) | CASP3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL6379411 | 0.84 | MAPT (0.58) | ALDH1A1MAPTKLK7HPGDALOX15 | |
| SCHEMBL22500626 | 0.84 | HSD17B10 (0.54) | ALDH1A1MEN1KMT2AMAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| EP-1504002-B1 | METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE BETA-AMINOKETONES AND OPTICALLY ACTIVE 1,3-AMINOALCOHOLS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-12-19 | — | — | EP | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-7161008-B2 | Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | Sanofi - Aventis Deutschland GmbH (DE) | 2007-01-09 | — | — | US | claimed |
| EP-1504002-A1 | OPTICALLY ACTIVE &bgr;-AMINOKETONES, OPTICALLY ACTIVE 1,3-AMINOALCOHOLS AND METHOD FOR THE PRODUCTION THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-02-09 | — | — | EP | claimed |
| US-20040030145-A1 | Optically active B-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | claimed |
| WO-2003093259-A1 | OPTICALLY ACTIVE β-AMINOKETONES, OPTICALLY ACTIVE 1,3-AMINOALCOHOLS AND METHOD FOR THE PRODUCTION THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | WO | claimed |
| US-5663354-A | Process for preparing enantiomerically pure 6-[(4-chlorophenyl) (1H-1,2,4-triazol-1-yl) methyl]-1-methyl-1H-benzotrizole | JANSSEN PHARMACEUTICA, N.V. (BE) | 1997-09-02 | — | — | US | claimed |
| EP-0668861-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 6- (4-CHLOROPHENYL)(1H --TRIAZOL-1,2,4-TRIAZOL-1-YL)METHYL]-1-METHYL-1H --BENZOTRIAZOLE | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-08-30 | — | — | EP | claimed |
| WO-1994011364-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 6-[(4-CHLOROPHENYL)(1H^_-TRIAZOL-1,2,4-TRIAZOL-1-YL)METHYL]-1-METHYL-1H^_-BENZOTRIAZOLE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-05-26 | — | — | WO | claimed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-1994011364-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 6-[(4-CHLOROPHENYL)(1H^_-TRIAZOL-1,2,4-TRIAZOL-1-YL)METHYL]-1-METHYL-1H^_-BENZOTRIAZOLE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-05-26 | — | — | WO | disclosed |
| EP-0511558-A2 | Process for the resolution of racemates and associates of diastereoisomers | F. HOFFMANN-LA ROCHE AG (CH) | 1992-11-04 | — | — | EP | disclosed |
| US-4988734-A | Fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | CASP3 4137/4885ALDH1A1 3087/4885MEN1 4428/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | CASP3 2027/4885ALDH1A1 4675/4885MEN1 4405/4885 |
| US-20040030145-A1 | Optically active B-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | ORMDL3, OR10J3, BCAT2 | CASP3 2179/4885ALDH1A1 59/4885MEN1 3531/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | CASP3 4137/4885ALDH1A1 3087/4885MEN1 4428/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | CASP3 4137/4885ALDH1A1 3087/4885MEN1 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.